Four companies raise nearly $950M in follow-ons: Public Equity Report

Among public companies raising cash opportunistically this week, some took advantage of catalysts of their own, while others rode valuation bumps in sympathy with other companies’ news.

Nuvalent Inc. (NASDAQ:NUVL) had a busy week, raising $500 million shortly after announcing a clinical readout for small molecule ALK inhibitor neladalkib — and just before revealing that its NDA for ROS1 inhibitor zidesamtinib was accepted for FDA review to treat a targeted population of non-small cell lung cancer (NSCLC) patients...